Company intelligence / Profile preview

Apricot Capital

Shanghai, Shanghai Municipality, China

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Apricot Capital is a leading investment firm focused on early- and growth-stage companies in biotech, medtech, and life science. It has a mission to bridge China's biotech sector with global healthcare markets.

Modalities: Gene TherapyGene EditingCell TherapyNucleic Acid DrugsConjugate DrugsProtein DegradationAntibodySmall Molecule Pharmaceuticals
Industry: Investors

Beyond the preview

Go deeper on Apricot Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apricot Capital.

Explore the full profile